Vanguard Group Inc ownership in RYTM / Rhythm Pharmaceuticals, Inc.

Rhythm Pharmaceuticals, Inc.

US ˙ NasdaqGM ˙ US76243J1051

Security	RYTM / Rhythm Pharmaceuticals, Inc.
Institution	Vanguard Group Inc
Latest Disclosed Ownership	0 shares
Ownership	0.00%

2026-03-27 - Vanguard Group Inc has filed an SCHEDULE 13G/A form with the Securities and Exchange Commission (SEC) disclosing ownership of 0 shares of Rhythm Pharmaceuticals, Inc. (US:RYTM). This represents 0.0 percent ownership of the company. In their previous filing dated 2026-01-30 , Vanguard Group Inc had reported owning 6,210,916 shares, indicating a decrease of -100.00 percent.

Institutional Ownership: 13D/G Filings

This table shows a history of the 13D/G filings made by the investor and/or investor group. Note that the share values in this table are not directly comparable to any numbers shown in the 13F table (if any).

File Date	Effective Date	Form	Prev Shares	Latest Shares	ΔShares (Percent)	Ownership (Percent)	ΔOwnership (Percent)
2026-03-27	2026-03-27	13G/A	6,210,916	0	-100.00	0.00	-100.00
2026-01-30	2026-01-30	13G/A	4,996,427	6,210,916	24.31	9.30	23.67
2025-10-30	2025-10-30	13G/A	3,226,938	4,996,427	54.83	7.52	37.73
2024-02-13	2024-02-13	13G		3,226,938		5.46

Important Note: One of the primary uses of the 13D/G filings is to evaluate the ability of a firm to control a company (ie, the "beneficial ownership"). To that end, firms are required to report not just direct holdings in companies, but indirect holdings that they control. For investment firms, these indirect holdings can include shares in funds they manage, advisory accounts, and in the case of activist campaigns, pledged votes. Therefore, share counts listed in 13D/G filings can differ significantly than share counts listed in 13F filings.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel Premium Registration Required .

Disclosed Equity Positions (from 13F/NPORT Filings)

File Date	Effective Date	Form	Security	Class	ID	Reported Shares	ΔShares	ΔShares (%)	Reported Value (x1000)	ΔValue (%)	Alloc (%)
2026-01-29	2025-12-31	13F	RHYTHM PHARMACEUTICALS	COM	76243J105	6,210,916	1,214,489	24.31	664,816	31.75	0.0096
2025-11-07	2025-09-30	13F	RHYTHM PHARMACEUTICALS	COM	76243J105	4,996,427	1,407,313	39.21	504,589	122.49	0.0076
2025-08-11	2025-06-30	13F	RHYTHM PHARMACEUTICALS	COM	76243J105	3,589,114	144,188	4.19	226,796	24.29	0.0037
2025-05-09	2025-03-31	13F	RHYTHM PHARMACEUTICALS	COM	76243J105	3,444,926	2,326	0.07	182,478	-5.31	0.0033
2025-02-11	2024-12-31	13F	RHYTHM PHARMACEUTICALS	COM	76243J105	3,442,600	-5,311	-0.15	192,717	6.69	0.0034
2024-11-13	2024-09-30	13F	RHYTHM PHARMACEUTICALS	COM	76243J105	3,447,911	87,216	2.60	180,636	30.91	0.0032
2024-08-13	2024-06-30	13F	RHYTHM PHARMACEUTICALS	COM	76243J105	3,360,695	56,549	1.71	137,990	-3.62	0.0027
2024-05-10	2024-03-31	13F	RHYTHM PHARMACEUTICALS	COM	76243J105	3,304,146	77,208	2.39	143,169	-3.49	0.0028
2024-03-11	2023-12-31	13F/A-1	RHYTHM PHARMACEUTICALS	COM	76243J105	3,226,938	212,370	7.04	148,342	114.65	0.0032
2024-02-14	2023-12-31	13F	RHYTHM PHARMACEUTICALS	COM	76243J105	3,226,938	212,370		148,342		0.0028
2023-12-18	2023-09-30	13F/A-1	RHYTHM PHARMACEUTICALS	COM	76243J105	3,014,568	85,139	2.91	69,109	43.06	0.0017
2023-11-14	2023-09-30	13F	RHYTHM PHARMACEUTICALS	COM	76243J105	3,014,568	85,139		69,109		0.0017
2023-08-14	2023-06-30	13F	RHYTHM PHARMACEUTICALS	COM	76243J105	2,929,429	281,293	10.62	48,306	2.25	0.0011
2023-07-14	2023-03-31	13F/A-1	RHYTHM PHARMACEUTICALS	COM	76243J105	2,648,136	51,822	2.00	47,243	-37.51	0.0012
2023-05-15	2023-03-31	13F	RHYTHM PHARMACEUTICALS	COM	76243J105	2,648,136	51,822		47,243		0.0012
2023-02-10	2022-12-31	13F	RHYTHM PHARMACEUTICALS	COM	76243J105	2,596,314	362,042	16.20	75,605	38.12	0.0021
2022-11-14	2022-09-30	13F	RHYTHM PHARMACEUTICALS	COM	76243J105	2,234,272	84,546	3.93	54,739	513.53	0.0016
2022-08-12	2022-06-30	13F	RHYTHM PHARMACEUTICALS	COM	76243J105	2,149,726	-107,294	-4.75	8,922	-65.69	0.0003
2022-05-13	2022-03-31	13F	RHYTHM PHARMACEUTICALS	COM	76243J105	2,257,020	-66,501	-2.86	26,001	12.13	0.0006
2022-02-14	2021-12-31	13F	RHYTHM PHARMACEUTICALS	COM	76243J105	2,323,521	10,443	0.45	23,188	-23.24	0.0005
2021-11-12	2021-09-30	13F	RHYTHM PHARMACEUTICALS	COM	76243J105	2,313,078	55,656	2.47	30,209	-31.65	0.0008
2021-08-13	2021-06-30	13F	RHYTHM PHARMACEUTICALS	COM	76243J105	2,257,422	5,027	0.22	44,200	-7.74	0.0011
2021-05-14	2021-03-31	13F	RHYTHM PHARMACEUTICALS	COM	76243J105	2,252,395	366,871	19.46	47,908	-14.54	0.0013
2021-02-12	2020-12-31	13F	RHYTHM PHARMACEUTICALS	COM	76243J105	1,885,524	-5,514	-0.29	56,056	36.79	0.0016
2020-11-16	2020-09-30	13F	RHYTHM PHARMACEUTICALS	COM	76243J105	1,891,038	-79,985	-4.06	40,980	-6.77	0.0014
2020-08-14	2020-06-30	13F	RHYTHM PHARMACEUTICALS	COM	76243J105	1,971,023	260,210	15.21	43,954	68.80	0.0016
2020-05-15	2020-03-31	13F	RHYTHM PHARMACEUTICALS	COM	76243J105	1,710,813	31,340	1.87	26,039	-32.47	0.0011
2020-02-14	2019-12-31	13F	RHYTHM PHARMACEUTICALS	COM	76243J105	1,679,473	400,194	31.28	38,561	39.61	0.0013
2019-11-14	2019-09-30	13F	RHYTHM PHARMACEUTICALS	COM	76243J105	1,279,279	92,019	7.75	27,620	5.74	0.0010
2019-08-14	2019-06-30	13F	RHYTHM PHARMACEUTICALS	COM	76243J105	1,187,260	35,270	3.06	26,120	-17.28	0.0010
2019-05-15	2019-03-31	13F	RHYTHM PHARMACEUTICALS	COM	76243J105	1,151,990	69,525	6.42	31,575	8.52	0.0012
2019-02-14	2018-12-31	13F	RHYTHM PHARMACEUTICALS	COM	76243J105	1,082,465	34,279	3.27	29,096	-4.84	0.0013
2018-12-13	2018-09-30	13F/A-2	RHYTHM PHARMACEUTICALS	COM	76243J105	1,048,186	115,177	12.34	30,575	4.83	0.0012
2018-11-23	2018-09-30	13F/A-1	RHYTHM PHARMACEUTICALS	COM	76243J105	1,048,186	0		30,575		0.0012
2018-11-14	2018-09-30	13F	RHYTHM PHARMACEUTICALS	COM	76243J105	1,048,186	115,177		30,575
2018-08-14	2018-06-30	13F	RHYTHM PHARMACEUTICALS	COM	76243J105	933,009	530,097	131.57	29,166	263.76	0.0012
2018-05-15	2018-03-31	13F	RHYTHM PHARMACEUTICALS	COM	76243J105	402,912	-74,521	-15.61	8,018	-42.21	0.0004
2018-02-14	2017-12-31	13F	RHYTHM PHARMACEUTICALS	COM	76243J105	477,433	477,433		13,875		0.0006

Legend

Shares: The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value: The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price: The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class: This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred

Allocation (%): The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation: The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%): The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis: The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss: This is the market value of the position as of the effective date minus the cost basis.